Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience

被引:5
|
作者
Bahig, Houda [1 ,2 ]
Ehab, Hanna Y. Y. [3 ]
Garden, Adam S. S. [1 ]
Ng, Sweet Ping [1 ,4 ]
Frank, Steven J. J. [1 ]
Nguyen, Theresa [1 ]
Gunn, Gary B. B. [1 ]
Rosenthal, David I. I. [1 ]
Fuller, Clifton D. D. [1 ]
Ferrarotto, Renata [5 ]
Bell, Diana [6 ]
Su, Shirley [3 ]
Phan, Jack [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 0097, Houston, TX 77030 USA
[2] Ctr Hosp Univ Montreal, Dept Radiat Oncol, Montreal, PQ, Canada
[3] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[4] Austin Hlth, Olivia Newton John Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[5] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
conformal radiotherapy; head and neck cancer; IMRT; IMPT; intensity modulated radiation therapy; proton therapy; paranasal sinus cancer; radiation therapy; radiotherapy; sinonasal tumors; SNUC; SCC; VMAT; INTENSITY-MODULATED RADIOTHERAPY; PARANASAL SINUS CANCER; NASAL CAVITY; RADIATION-THERAPY; MAXILLARY SINUS; UNDIFFERENTIATED CARCINOMA; PROGNOSTIC-FACTORS; CLINICAL-OUTCOMES; PROTON THERAPY; PHOTON THERAPY;
D O I
10.1002/hed.27381
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
PurposeTo report long-term outcomes of modern radiotherapy for sinonasal cancers. Methods and materialsA retrospective analysis of patients with sinonasal tumors treated with intensity-modulated radiotherapy or proton therapy. Multivariate analysis was used to determine predictive variables of progression free survival (PFS) and overall survival (OS). ResultsThree hundred and eleven patients were included, with median follow-up of 75 months. The most common histologies were squamous cell (42%), adenoid cystic (15%), and sinonasal undifferentiated carcinoma (15%). Induction chemotherapy was administered to 47% of patients; 68% had adjuvant radiotherapy. Ten-year local control, regional control, distant metastasis free survival, PFS, and overall survival rates were 73%, 88%, 47%, 32%, and 51%, respectively. Age, non-nasal cavity tumor site, T3-4 stage, neck dissection, and radiation dose were predictive of PFS, while age, non-nasal cavity tumor site, T3-4 stage, positive margins, neck dissection, and use of neoadjuvant chemotherapy were predictive of OS. There was a 13% rate of late grade >= 3 toxicities. ConclusionThis cohort of patients with sinonasal cancer treated with modern radiotherapy demonstrates favorable disease control rate and acceptable toxicity profile.
引用
收藏
页码:1692 / 1703
页数:12
相关论文
共 50 条
  • [1] M. D. Anderson experience in the clinical management of growing teratoma syndrome
    Spiess, PE
    Kassouf, W
    Brown, GA
    Kamat, AM
    Gomez, JA
    Evans, J
    Pisters, LL
    JOURNAL OF UROLOGY, 2006, 175 (04): : 145 - 145
  • [2] Multimodality management of urachal carcinoma: The M. D. Anderson Cancer Center experience
    Siefker-Radtke, AO
    Gee, J
    Shen, Y
    Wen, SJ
    Daliani, D
    Millikan, RE
    Pisters, LL
    JOURNAL OF UROLOGY, 2003, 169 (04): : 1295 - 1298
  • [3] Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
    Kuban, Deborah A.
    Tucker, Susan L.
    Dong, Lei
    Starkschall, George
    Huang, Eugene E.
    Cheung, M. Rex
    Lee, Andrew K.
    Pollack, Alan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 70 (01): : 67 - 74
  • [4] Surgical management of growing teratoma syndrome: The M. D. Anderson Cancer Center Experience
    Spiess, Philippe E.
    Kassouf, Wassim
    Brown, Gordon A.
    Kamat, Ashish M.
    Liu, Ping
    Gomez, Jose A.
    Tu, Shi-Ming
    Tannir, Nizar M.
    Pisters, Louis L.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 1330 - 1334
  • [5] Is there a role for surgery in the management of metastatic urothelial cancer? An update of the M. D. Anderson experience
    Siefker-Radtke, A
    Walsh, GL
    Swanson, DA
    Logothetis, CJ
    Millikan, RE
    JOURNAL OF UROLOGY, 2002, 167 (04): : 283 - 283
  • [6] Management of patients with systemic mastocytosis:: Review of M. D.!Anderson cancer center experience
    Hennessy, B
    Giles, F
    Cortes, J
    O'Brien, S
    Ferrajoli, A
    Ossa, G
    García-Manero, G
    Faderl, S
    Kantarjian, H
    Verstovsek, S
    AMERICAN JOURNAL OF HEMATOLOGY, 2004, 77 (03) : 209 - 214
  • [7] Adenocarcinoma of the lung in young patients - The M. D. Anderson experience
    Liu, NS
    Spitz, MR
    Kemp, BL
    Cooksley, C
    Fossella, FV
    Lee, JS
    Hong, WK
    Khuri, FR
    CANCER, 2000, 88 (08) : 1837 - 1841
  • [8] Long-term Outcomes from Proton Therapy for Sinonasal Cancers
    Dagan, Roi
    Uezono, Haruka
    Bryant, Curtis
    Holtzman, Adam L.
    Morris, Christopher G.
    Mendenhall, William M.
    INTERNATIONAL JOURNAL OF PARTICLE THERAPY, 2021, 8 (01) : 200 - 212
  • [9] Health profiles of 996 melanoma survivors: the M. D. Anderson experience
    Charles Stava
    Martha Beck
    L Todd Weiss
    Adriana Lopez
    Rena Vassilopoulou-Sellin
    BMC Cancer, 6
  • [10] Health profiles of 996 melanoma survivors: the M. D. Anderson experience
    Stava, Charles
    Beck, Martha
    Weiss, L. Todd
    Lopez, Adriana
    Vassilopoulou-Sellin, Rena
    BMC CANCER, 2006, 6 (1)